Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

Mathias J Rummel, MD PhD, Christian Lerchenmüller, MD, Manfred Hensel, MD, Martin Goerner, MD, Christian Buske, MD PhD, Holger Schulz, Burkhard Schmidt, MD, Georgi Kojouharoff, MD, Elisabeth Lange, MD, Wolfgang Willenbacher, MD PhD, Jan Dürig, Erik Engel, Frank Kauff, Jürgen Barth, Alexander Christoph Burchardt, MD, Axel Hinke, PhD, Jasmin Wupperfeld, Richard Greil, MD

Blood (2019) 134 (Supplement_1): 343.

https://doi.org/10.1182/blood-2019-121909

Published: 2019

Journal Articles

A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis

Wojciech Jurczak, MD PhD, Pier Luigi Zinzani, MD PhD, Georg Hess, Gianluca Gaidano, MD PhD, Mariano Provencio, MD, Zsolt Nagy, MD PhD, Tadeusz Robak, MD, Kami J. Maddocks, MD, Christian Buske, MD PhD, Sumeet Ambarkhane, MD MBBS, Wolfram Brugger, Maren Dirnberger-Hertweck, PhD, Sascha Tillmanns, Johannes Weirather, PhD, Kristie Blum

Blood (2019) 134 (Supplement_1): 4078.

https://doi.org/10.1182/blood-2019-124297

Published: 2019

Journal Articles

ME-401-003 (TIDAL): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Continuous and Intermittent Dosing Schedules in Patients with Relapsed/Refractory Follicular Lymphoma

Andrew D. Zelenetz, MD PhD, Pier Luigi Luigi Zinzani, MD, Henry Chan, MBChB, Christian Buske, MD PhD, Vincent Ribrag, David Cunningham, MD FRCP, FMedSci, Wojciech Jurczak, Pau Abrisqueta, MD PhD, Joanne Li, Igor Gorbatchevsky, MD, Jennifer R. Brown, MD PhD

Blood (2019) 134 (Supplement_1): 5244.

https://doi.org/10.1182/blood-2019-124326

Published: 2019

Journal Articles

Long-Term Efficacy and Safety Results of CT-P10 and Reference Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma: Phase III Updated Study Results with Median Follow-up of 40 Months

Christian Buske, MD PhD, Larry W Kwak, MD PhD, Wojciech Jurczak, MD PhD, Juan-Manuel Sancho, MD PhD, Edvard Zhavrid, MD PhD, Jin Seok Kim, MD PhD, Jose Angel Hernandez-Rivas, MD PhD, Aliaksandr Prokharau, MD PhD, Mariana Vasilica, MD PhD, Rajnish Nagarkar, MD PhD, Gayane Tumyan, DMSc, MD PhD, Won-Seog Kim, MD PhD, Michinori Ogura, MD PhD, Sang Joon Lee, PhD, Sung Hyun Kim, PhD, Keum Young Ahn, PhD

Blood (2019) 134 (Supplement_1): 1528.

https://doi.org/10.1182/blood-2019-126379

Published: 2019

Journal Articles

High Antileukemic Efficacy and Shortened Neutropenia of Dose-Dense Induction (Sequential-HAM Followed by Pegfilgrastim) in Primary Acute Myeloid Leukemia - Results of a Pilot Study of the German AML-CG.

Jan Braess, MD, PhD, Karsten Spiekermann, MD, PhD, Christian Buske, MD, PhD, Peter Staib, MD, PhD, Wolf-Dieter Ludwig, MD, PhD, Andreas Gruneisen, MD, Christa Sauerland, PhD, Michael Unterhalt, MD, PhD, Michael Fiegl, MD, Bernhard Wormann, MD, PhD, Wolfgang Kern, MD, PhD, Achim Heinicke, PhD, Wolfgang Berdel, MD, PhD, Thomas Büchner, MD, PhD, Wolfgang Hiddemann, MD, PhD

Blood (2007) 110 (11): 295.

https://doi.org/10.1182/blood.V110.11.295.295

Published: 2007

Journal Articles

Rituximab Is the Essential Treatment Modality That Underlies the Significant Improvement in Short and Long Term Outcome of Patients with Advanced Stage Follicular Lymphoma - A 10 Year Analysis of GLSG Trials.

Wolfgang Hiddemann, MD, PhD, Eva Hoster, MSc, Christian Buske, MD, PhD, Martin Dreyling, MD, PhD, Michael Kneba, MD, PhD, Michael Hallek, MD, PhD, Eva Lengfelder, MD, Hannes Wandt, MD, PhD, Michael Unterhalt, MD

Blood (2006) 108 (11): 483.

https://doi.org/10.1182/blood.V108.11.483.483

Published: 2006

Journal Articles

Combined Immuno-Chemotherapy (R-CHOP) Results in Significantly Superior Response Rates and Time to Treatment Failure in First Line Treatment of Patients with Lymphomplasmocytoid/ic Immunocytoma (LP-IC) - Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).

Christian Buske, MD, PhD, Martin H. Dreyling, MD, PhD, Hartmut Eimermacher, MD, Hans-Peter Boeck, MD, Michael Pfreundschuh, MD, PhD, Bernd Metzner, MD, Roland Fuchs, MD, PhD, Bernhard Woermann, MD, PhD, Lorenz H. Truemper, MD, PhD, Georg Hess, MD, Hannes Wandt, MD, PhD, Wolf-Dieter Ludwig, MD, PhD, Ernst-Dietrich Kreuser, MD, PhD, Joerg Schimke, MD, H.-J. Weh, MD, PhD, Stephan Schmitz, MD, PhD, W. Schmiegel, MD, PhD, Michael Unterhalt, MD, Wolfgang Hiddemann, MD, PhD

Blood (2004) 104 (11): 162.

https://doi.org/10.1182/blood.V104.11.162.162

Published: 2004

NARROW

Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis

ME-401-003 (TIDAL): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Continuous and Intermittent Dosing Schedules in Patients with Relapsed/Refractory Follicular Lymphoma

Long-Term Efficacy and Safety Results of CT-P10 and Reference Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma: Phase III Updated Study Results with Median Follow-up of 40 Months

High Antileukemic Efficacy and Shortened Neutropenia of Dose-Dense Induction (Sequential-HAM Followed by Pegfilgrastim) in Primary Acute Myeloid Leukemia - Results of a Pilot Study of the German AML-CG.

Rituximab Is the Essential Treatment Modality That Underlies the Significant Improvement in Short and Long Term Outcome of Patients with Advanced Stage Follicular Lymphoma - A 10 Year Analysis of GLSG Trials.

Combined Immuno-Chemotherapy (R-CHOP) Results in Significantly Superior Response Rates and Time to Treatment Failure in First Line Treatment of Patients with Lymphomplasmocytoid/ic Immunocytoma (LP-IC) - Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).

Email alerts

ASH Publications

American Society of Hematology

Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis

ME-401-003 (TIDAL): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Continuous and Intermittent Dosing Schedules in Patients with Relapsed/Refractory Follicular Lymphoma

Long-Term Efficacy and Safety Results of CT-P10 and Reference Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma: Phase III Updated Study Results with Median Follow-up of 40 Months

High Antileukemic Efficacy and Shortened Neutropenia of Dose-Dense Induction (Sequential-HAM Followed by Pegfilgrastim) in Primary Acute Myeloid Leukemia - Results of a Pilot Study of the German AML-CG.

Rituximab Is the Essential Treatment Modality That Underlies the Significant Improvement in Short and Long Term Outcome of Patients with Advanced Stage Follicular Lymphoma - A 10 Year Analysis of GLSG Trials.

Combined Immuno-Chemotherapy (R-CHOP) Results in Significantly Superior Response Rates and Time to Treatment Failure in First Line Treatment of Patients with Lymphomplasmocytoid/ic Immunocytoma (LP-IC) - Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only